Evaluation of mucoadhesive PLGA microparticles for nasal immunization

AAPS Journal

Volumn 12, Issue 2, 2010, Pages 130-137

  Pawar, Dilip ^a   Goyal, Amit K ^b   Mangal, Sharad ^a   Mishra, Neeraj ^a   Vaidya, Bhuvaneshwar ^a   Tiwari, Shailja ^a   Jain, Arvind K ^a   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b ISF COLLEGE OF PHARMACY   (India)

Author keywords

Chitosan; Microparticles; Mucosal vaccination; PLGA; Vaccine delivery

Indexed keywords

CHITOSAN; CHITOSAN DERIVATIVE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G; MUCIN; POLYGLACTIN; TRIMETHYL CHITOSAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN STRUCTURE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADSORPTION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; FLUORESCENCE MICROSCOPY; HEPATITIS B; HEPATITIS B VIRUS; IMMUNE COMPLEX DEPOSITION; IMMUNIZATION; LYMPHOID TISSUE; MATERIALS TESTING; MOUSE; MUCOADHESION; NONHUMAN; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ADMINISTRATION, INTRANASAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG CARRIERS; ELECTROCHEMISTRY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCIPIENTS; FEMALE; HEPATITIS B SURFACE ANTIGENS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LACTIC ACID; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, FLUORESCENCE; MUCINS; NANOPARTICLES; POLYGLYCOLIC ACID; TISSUE ADHESIVES; VACCINES;

EID: 77950666776     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9169-1     Document Type: Article

References (45)

1. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112-125 doi:10.1093/epirev/mxj009. (Pubitemid 44289094)
2. Gupta RK, Siber GR. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine. 1995;13:1263-1276 doi:10.1016/S0169-409X(01) 00167-3.
3. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11(4):45-53. doi:10.1111/j.1574-6968.1991.tb04964.x. (Pubitemid 40562303)
4. Illum L,Davis SS. Nasal vaccination: a non-invasive vaccine delivery method that holds great promise for the future.Adv Drug Deliv Rev. 2001;51:1-3. doi:10.1016/S0169-409X(01)00176-4. (Pubitemid 32763068)
5. Iqbal M, Lin W, Jabbal-Gill I, Davis SS, Steward MW, Illum L. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL response in BALB/c mice. Vaccine. 2003;21:1478-1485 doi:10.1016/S0264-410X(02)00662-X. (Pubitemid 36263189)
6. Moynihan JS, Jones DH, Farrar GH, Howard CR. A novel microencapsulated peptide vaccine against hepatitis B. Vaccine. 2001;19:3292-3300 doi:10.1016/S0264-410X(00)00540-5. (Pubitemid 32324061)
7. Jaganathan KS, Singh P, Prabakaran D, Mishra V, Vyas SP. Development of a single dose stabilized poly(D, L-lactic-coglycolic acid) microspheres-based vaccine against hepatitis B. J Pharm Pharmacol. 2004;56:1243-1250 doi:10.1211/0022357044418. (Pubitemid 39368994)
8. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release. 2002;78:15-24. doi:10.1016/S0168-3659(01)00486-2. (Pubitemid 34081849)
9. Koping-Hoggard M, Sanchez A, Alonso MJ. Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines. 2005;4:185-196 doi:10.1586/ 14760584.4.2.185. (Pubitemid 40525060)
10. Soane RJ, Ferier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of the clearance characteristics of bioadhesive system in humans. Int J Pharm. 1999;178:55-65. doi:10.1016/S0378-5173(98)00367-6. (Pubitemid 29074407)
11. Almeida AJ, Alpar HO, Brown MRW. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly (l-lactic acid) microspheres in rats, rabbits and guineapigs. J Pharm Pharmacol. 1993;45:198-203.
12. Alpar HO, Almeida AJ, Brown MRW. Microsphere absorption by the nasal mucosa of the rat. J Drug Target. 1994;2:147-149 doi:10.3109/10611869409015903.
13. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release. 2003;87:187-198 doi:10.1016/S0168-3659(02)00363-2. (Pubitemid 36255456)
14. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayer of intestinal epithelial cells (Caco-2). Pharm Res. 1994;11:1358-1361 doi:10.1023/A:1018967116988. (Pubitemid 24287420)
15. Borchard G, Lueßen HL, de Boer AG, Verhoef JC, Lehr CM, Junginger HE. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: effects of chitosanglutamate and carbomer on epithelial tight junctions in vitro. J Control Release. 1996;39:131-138 doi:10.1016/0168-3659(95) 00146-8. (Pubitemid 26194212)
16. Soane RJ, Hinchcliffe M, Davis SS, Illum L. Clearance characteristics of chitosan based formulation in the sheep nasal cavity. Int J Pharm. 2001;217:183-191 doi:10.1016/S0378-5173(01)00602-0. (Pubitemid 32268644)
17. Bivas-Benita M, Laloup M, Versteyhe S, Dewit J, De Braekeleer J, Jongert E, et al. Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization, and preliminary in vivo studies. Int J Pharm. 2003;266:17-27. doi:10.1016/S0378-5173(03)00377-6. (Pubitemid 37249304)
18. van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Verhoef JC, Junginger HE. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine. 2003;28:1400-1408 doi:10.1016/S0264- 410X(02)00686-2. (Pubitemid 36263181)
19. Vila A, Sanchez A, Janes K, Behrens I, Kissel T, Vila Jato JL, et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm. 2004;57:123-131 doi:10.1016/j.ejpb.2003. 09.006. (Pubitemid 38058811)
20. Atyabia F, Moghaddama FA, Dinarvanda R, Zohuriaan-Mehrd MJ, Ponchele G. Thiolated chitosan coated poly hydroxyethyl methacrylate nanoparticles: synthesis and characterization. Carbohydr Polym. 2008;74(1):59-67. doi:10.1016/j.carbpol.2008.01.015.
21. Jaganathan KS, Vyas SP. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine. 2006;24:4201-4211 doi:10.1016/j.vaccine. 2006.01.011.
22. Ravi Kumar MNV, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004;25:1771-1777 doi:10.1016/j.biomaterials.2003.08.069. (Pubitemid 38102253)
23. Schipper NG, Olsson S, Hoogstraate JA. deBoer AG, Varum KM, Artursson P. Chitosan as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm Res. 1997;14:923-929 doi:10.1023/A:1012160102740. (Pubitemid 27326989)
24. Kotzé AF, Luessen HL, de Leeuw BJ, de Boer AG, Verhoef JC, Junginger HE. Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). J Control Release. 1998;51:35-46. doi:10.1016/S0168-3659(97)00154-5. (Pubitemid 28064643)
25. Thanou MM, Kotze AF, Scharringhausen T, Luessen HL, de Boer AG, Verhoef JC, et al. Effect of degree of quaternization of N-trimethyl chitosan chloride for enhanced transport of hydrophilic compounds across intestinal caco-2 cell monolayers. J Control Release. 2000;64:15-25. doi:10.1016/S0168-3659(99)00131-5. (Pubitemid 30035304)
26. Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev. 2001;52:117-126 doi:10.1016/S0169-409X(01)00231-9. (Pubitemid 33079167)
27. Sadeghi AMM, Dorkoosh FA, Avadi MR, Weinhold M, Bayat A, Delie F, et al. Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur J Pharm Biopharm. 2008;70:270-278 doi:10.1016/j.ejpb.2008.03.004.
28. Sieval AB, Thanou M, Kotze AF, Verhoef JC, Brussee J, Junginger HE. Preparation and NMR characterization of highly substituted N-trimethyl chitosan chloride. Carbohydr Polym. 1998;36:157-165 doi:10.1016/S0144-8617(98)00009-5. (Pubitemid 128399589)
29. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Rice TR. Controlled vaccine release in the gut associated lymphoid tissues. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release. 1990;11:205-214 doi:10.1016/0168-3659(90)90133-E.
30. Khatri K, Goyal AK, Gupta PN, Mishra N, Mehta A, Vyas SP. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine. 2008;26:225-2233. doi:10.1016/j.vaccine.2008.02.058.
31. Vajdy M, O'Hagan DT. Microparticles for intranasal immunization. Adv Drug Deliv Rev. 2001;51:127-141 doi:10.1016/S0169-409X(01)00167-3. (Pubitemid 32763077)
32. Debin A, Kravtzoff R, Santiago JV, Cazales L, Sperandio S, Melber K, et al. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine. 2002;20:2752-2763 doi:10.1016/S0264-410X(02)00191-3. (Pubitemid 34601001)
33. Jain S, Singh P, Mishra V, Vyas SP. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B. Immunol Lett. 2005;101(1):41-49 doi:10.1016/j.imlet.2005.04.002. (Pubitemid 41297497)
34. Smith MW, Thomas NW, Jenkins NW, Miller PG, Cremaschi NGA, Porta C. Selective transport of microparticles across Peyer's patches follicle associated M cells from mice and rats. Exp Physiol. 1995;80:735-743
35. Jani PU, McCarthy DE, Florence AT. Nanosphere and microsphere uptake via Peyer's patches: observation of the rate of uptake after a single oral dose. Int J Pharm. 1992;86:239-246 doi:10.1016/0378-5173(92)90202-D.
36. Almeida AJ, Alpar HO. Nasal delivery of vaccines. J Drug Target. 1996;3:455-467 doi:10.3109/10611869609015965.
37. Kuper CF, Koornstra PJ, Hameleers DM, Biewenga J, Spit BJ, Duijvestijn AM, et al. The role of nasopharyngeal lymphoid tissue. Immunol Today. 1992;13:219-224
38. Kiyono H, Fukuyama S. NALT versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol. 2004;4:699-710. doi:10.1038/nri1439. (Pubitemid 39223076)
39. Ito R, Ozaki YA, Yoshikawa T, Hasegawa H, Sato Y, Suzuki Y, et al. Roles of antihemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine. 2003;21:2362-2371 doi:10.1016/S0264-410X(03)00078-1. (Pubitemid 36561328)
40. Huang Y, Donovan MD. Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption. Adv Drug Deliv Rev. 1998;29:147-155 (Pubitemid 28044091)
41. Desai M, Labhasetwar V, Amidon G, Levy R. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 1996;13:1838-1845 doi:10.1016/S0169-409X(97)00066-5. (Pubitemid 27034116)
42. Delie F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv Drug Deliv Rev. 1998;34:221-233 doi:10.1016/S0169- 409X(98)00041-6. (Pubitemid 28535113)
43. Brooking J, Davis SS, Illum L. Transport of nanoparticles across the rat nasal mucosa. J Drug Target. 2001;9:267-79. (Pubitemid 32776362)
44. Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005;57(11):1556-1568 doi:10.1016/j.addr.2005.07.001. (Pubitemid 41443469)
45. Peppas NA, Buri PA. Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissues. J Control Release. 1985;2:257-275 doi:10.1016/0168-3659(85)90050-1.